The generic name for Adenosine is adenosine.
What is adenosine used for?
Adenosine is a naturally occurring substance in the body that plays a role in various physiological processes. Medically, it is used intravenously as an antiarrhythmic medication to treat certain types of supraventricular tachycardia (SVT). It works by slowing electrical conduction through the AV node of the heart, which can interrupt reentrant pathways causing SVT.
How does adenosine work to treat SVT?
Adenosine acts by briefly slowing the heart rate and widening blood vessels. When administered intravenously, it has a very short half-life, meaning it is quickly metabolized. Its primary mechanism in SVT involves its action on the atrioventricular (AV) node, where it prolongs the refractory period, thereby blocking reentrant circuits that perpetuate SVT.
What are the common side effects of adenosine?
Common side effects experienced by patients receiving adenosine include a sensation of flushing, shortness of breath or chest discomfort, nausea, dizziness, and headache. These effects are typically transient due to the drug's rapid metabolism.
When does adenosine patent exclusivity expire?
Information regarding the specific patent exclusivity for adenosine can be found on DrugPatentWatch.com [1]. Patent expiration dates determine when generic versions of a drug can enter the market.
Are there other medications for supraventricular tachycardia?
Yes, other medications can be used to treat supraventricular tachycardia, depending on the specific type of SVT and patient factors. These may include beta-blockers, calcium channel blockers, and antiarrhythmic drugs like amiodarone.
What is the difference between adenosine and other antiarrhythmics?
Adenosine is unique among antiarrhythmics due to its rapid onset, short duration of action, and specific mechanism targeting the AV node. Other antiarrhythmics have broader mechanisms of action and longer durations, requiring different administration routes and management strategies.
Can adenosine be used for other heart conditions?
While adenosine's primary approved indication is for the treatment of specific supraventricular tachycardias, it is also used diagnostically to help identify certain heart rhythm abnormalities during electrophysiology studies.
What happens if adenosine is not effective for SVT?
If adenosine is not effective in converting SVT to a normal rhythm, or if it is contraindicated, healthcare providers will consider alternative treatment strategies. These may include vagal maneuvers, cardioversion, or the use of other antiarrhythmic medications.
How is adenosine administered?
Adenosine is administered intravenously, usually as a rapid bolus injection, given its very short half-life. This rapid delivery ensures it reaches the heart quickly to exert its effect.
Where can I find more information on adenosine's drug patents?
More detailed information regarding adenosine's drug patents, including expiration dates and any ongoing litigation, can be accessed through DrugPatentWatch.com [1].
Are there generic versions of adenosine available?
The availability of generic versions of adenosine depends on the expiration of relevant patents. DrugPatentWatch.com tracks these patent expiries and can provide information on when generic competition is expected [1].
What are the risks of using adenosine?
Potential risks associated with adenosine use include transient heart block, bradycardia, hypotension, and bronchospasm, particularly in patients with asthma. Close medical supervision is necessary during administration.
Who makes adenosine?
The original developer and manufacturers of branded adenosine may differ from companies producing generic versions. Information on specific manufacturers can typically be found through pharmaceutical databases and DrugPatentWatch.com, which also tracks patent holders and potential generic manufacturers [1].
What are the clinical trial results for adenosine in SVT?
Clinical trials have demonstrated adenosine's high efficacy in converting recent-onset SVT to normal sinus rhythm. Studies typically report conversion rates often exceeding 90% with appropriate administration.
---
Sources:
1. DrugPatentWatch.com